Herantis Taps Spark Therapeutics Veteran as CMO to Advance Parkinson’s Drug
Event summary
- Herantis appoints Dr. Juha Savola as Chief Medical Officer, bringing 25+ years of drug development experience in neurology and gene therapy.
- Savola previously led clinical programs at Spark Therapeutics, including Parkinson’s disease and Huntington’s disease treatments.
- HER-096, Herantis’ lead candidate, is set to enter Phase 2 trials in 2027 after showing safety in a Phase 1b study.
The big picture
Herantis’ appointment of Savola underscores its push toward regulatory and commercial readiness for HER-096, a critical move as Parkinson’s disease therapies remain an underserved market. The hire signals confidence in navigating complex neurology drug development, where clinical validation remains the primary hurdle.
What we're watching
- Clinical Milestones
- Whether HER-096 can demonstrate efficacy in Phase 2 trials, validating its disease-modifying potential for Parkinson’s.
- Regulatory Strategy
- How Savola’s FDA and EMA experience will shape Herantis’ global regulatory approach.
- Partnering Dynamics
- The pace at which Herantis secures strategic collaborations to advance HER-096 beyond Phase 2.
Related topics